A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
ACTIVE_NOT_RECRUITING
Status
Conditions
- Progressive Supranuclear Palsy
Interventions
- DRUG: UCB0107 (bepranemab)
Sponsor
UCB Biopharma SRL